CYT003

BIOLOGICAL2 trials

Sponsors

Cytos Biotechnology AG

Conditions

AsthmaModerate to Severe Allergic Asthma

Phase 2

CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma

TerminatedNCT01673672

Cytos Biotechnology AGModerate to Severe Allergic Asthma

Start: 2012-11-30End: 2014-05-31Updated: 2014-05-14

CYT003 in Patients With Mild to Moderate Allergic Asthma Not Sufficiently Controlled on Inhaled Glucocorticosteroids

WithdrawnNCT02087644

Cytos Biotechnology AGAsthma

Start: 2014-05-31Updated: 2014-05-14

Related Papers

CYT003-QbG10 Not Effective in Uncontrolled Allergic Asthma

MD Conference Express2014-08-01